Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
The DIPG/DMG National Tumor Board: The power of advocacy.
Journal: Neuro-oncology pediatrics
Published: August 06, 2026
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.
Journal: Neuro-oncology advances
Published: April 30, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups.
Journal: JCO clinical cancer informatics
Published: April 10, 2026
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 13, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.
Journal: Neuro-oncology
Published: January 19, 2026
Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma.
Journal: Neuro-oncology
Published: January 19, 2026
Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.
Journal: Neuro-oncology advances
Published: August 04, 2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation.
Journal: The Lancet. Oncology
Published: May 30, 2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art.
Journal: The Lancet. Oncology
Published: May 30, 2025
Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis.
Journal: Acta neuropathologica
Published: May 09, 2025
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
Journal: Neuro-oncology
Published: April 17, 2025
Last Updated: 09/26/2026